Details for Patent: 10,137,209

« Back to Dashboard

Which drugs does patent 10,137,209 protect, and when does it expire?

Patent 10,137,209 protects AMBELVIST and is included in one NDA.

This patent has sixty-three patent family members in forty-three countries.

Summary for Patent: 10,137,209

Title:	Gadolinium chelate compounds for use in magnetic resonance imaging
Abstract:	The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
Inventor(s):	Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
Assignee:	Bayer Pharma AG
Application Number:	US15/578,687
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,137,209

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-001	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-002	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-003	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-004	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-005	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-006	Jun 12, 2026		RX	Yes	Yes	10,137,209			Y		METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM)

International Family Members for US Patent 10,137,209

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	104897
Australia	2016272602
Brazil	112017026135
Canada	2987993
Chile	2017003083
China	107667096